Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results including the FENTORA clinical trials discussed herein; prospects for regulatory approval, including the timing of an sNDA filing for FENTORA; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance for the third quarter and full-year 2007; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 A victim of medical negligence at ... doctor with a history of alcohol abuse, a physician and ... Prop 46 today, highlighting how Prop 46 will identify and ... The ad pictures a doctor drinking at ... ER."  Proposition 46 will enact the first law in the ...
(Date:10/17/2014)... , Oct. 17, 2014  UBM Medica US announces ... for endocrinologists and other clinicians who treat patients with ... on effective use of insulin .  ... insulin replacement therapy – daily injections of ... progressive decline in the function of pancreatic beta cells. ...
(Date:10/17/2014)... ANDOVER, Mass. , Oct. 17, 2014   ... pulmonary function testing (PFT) employing precise ultrasound technology, announced ... the Choctaw Nation Healthcare Center , a 140,000 ... Talihina, Oklahoma hospital serves a ... in southeastern Oklahoma and beyond. ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... CyberKnife Coalition announced today that more than ... have now been enrolled in the first national patient ... treated with stereotactic body radiation therapy. The multi-institutional ... functional outcomes of men with localized prostate cancer treated ...
... 30, 2011   Takeda ... completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 ... Nycomed a wholly owned subsidiary of Takeda effective the ... of Nycomed in addition to his current role as ...
Cached Medicine Technology:First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2Takeda Completes Acquisition and Names New CEO of Nycomed 2Takeda Completes Acquisition and Names New CEO of Nycomed 3Takeda Completes Acquisition and Names New CEO of Nycomed 4
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... CO (PRWEB) October 20, 2014 ... assays are the only imaging assays capable of ... a single test.  With these three dimensions of ... ability to detect the widest range of disease-causing ... usually missed by other genomic tools, including today’s ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Feb. 18, 2008 Seattle Childrens Hospital Research Institute announced ... the Bill & Melinda Gates Foundation to study ways to ... over 1 million newborn babies worldwide each year. It ... States with over 10,000 babies dying each year. Over 3 ...
... remarks by President Bush., Meru District Hospital ... zenu. We have just toured the hospital here,which is on ... Doc, for leading the tour, and for your compassion. I ... to thank Minister,Mwakyusa for joining us here in Arusha. I,m ...
... other cells what to do, but new evidence suggests that, ... much to contribute, scientists say. , In an animal model, ... muscle cell fails to produce the protein beta-catenin, its neuron ... of the first proof that in vertebrates such as man, ...
... a variety of potentially toxic agents during pregnancy remains ... in society at large. However, there is now ... fetal and postnatal development of offspring and that this ... multidisciplinary symposium, sponsored by the American Association for the ...
... But many patients aren,t getting the lifesaving treatment, research ... clear that chemotherapy after breast cancer surgery increases survival ... potentially lifesaving treatment. , But, age shouldn,t be a ... to be a better predictor of positive results after ...
... A mathematical model that looks at different strategies ... and patient isolation may be effective approaches when ... era of superbugs, such as methicillin-resistant Staphylococcus aureas ... over bacterial infections, this type of modeling, if ...
Cached Medicine News:Health News:Researchers aim to prevent global prematurity and stillbirths 2Health News:Researchers aim to prevent global prematurity and stillbirths 3Health News:Remarks by President Bush on Malaria 2Health News:Remarks by President Bush on Malaria 3Health News:2-way cell talk provides clues about neuromuscular disease 2Health News:Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too 2Health News:Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too 3Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: